OSIMERTINIB

Description

Osimertinib – Targeted Therapy for EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)

Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) used in the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations (including T790M mutation). It is designed to cross the blood-brain barrier, making it highly effective in patients with brain metastases. Osimertinib provides superior progression-free survival and overall survival compared to earlier EGFR inhibitors.

At Oncomed Pharmacy, we supply authentic Osimertinib tablets from trusted manufacturers, ensuring patients receive high-quality, effective, and reliable targeted therapy.

Key Features of Osimertinib

• Indications:

o First-line treatment for EGFR-mutated NSCLC (exon 19 deletion or exon 21 L858R mutation)

o Second-line treatment for patients with T790M-positive NSCLC after progression on prior EGFR therapy

• Formulation: Oral tablets, commonly available in 40 mg and 80 mg strengths.
• Mechanism of Action: Selectively inhibits both EGFR-sensitizing mutations and the T790M resistance mutation, blocking tumor growth and spread.
• Patient Benefit: Effective against brain metastases, higher survival rates, and improved tolerability compared to first- and second-generation TKIs.

Why Buy Osimertinib from Oncomed Pharmacy?

• 100% genuine and quality-tested targeted therapy.
• Available in multiple tablet strengths for personalized dosing.
• Affordable pricing with safe countrywide delivery.
• Trusted oncology pharmacy specializing in lung cancer treatments and precision medicine.

Uses of Osimertinib

• First-Line NSCLC Treatment: For patients with EGFR mutation-positive tumors.
• Second-Line NSCLC Treatment: For patients with acquired T790M mutation after resistance to earlier EGFR inhibitors.
• CNS/Brain Metastases: Effective in controlling tumor spread within the brain.